	US 12,214,000 B2
	Human uterine cervical stem cell population and uses thereof
Francisco José Vizoso Piñeiro, Gijon (ES); Román Pérez Fernández, Santiago de Compostela (ES); and Noemí Eiró Díaz, Gijon (ES)
Assigned to GISTEM RESEARCH S.L., Gijon (ES)
Filed by GISTEM RESEARCH S.L., Gijon (ES)
Filed on Apr. 9, 2021, as Appl. No. 17/227,252.
Application 17/227,252 is a division of application No. 14/769,563, abandoned, previously published as PCT/EP2014/053508, filed on Feb. 24, 2014.
Claims priority of application No. 13156348 (EP), filed on Feb. 22, 2013.
Prior Publication US 2021/0299184 A1, Sep. 30, 2021
Int. Cl. A61K 35/48 (2015.01); C12N 5/071 (2010.01); C12N 5/074 (2010.01); C12N 5/077 (2010.01); C12N 5/0775 (2010.01)

CPC A61K 35/48 (2013.01) [C12N 5/0607 (2013.01); C12N 5/0661 (2013.01); C12N 5/0668 (2013.01); C12N 5/0682 (2013.01); C12N 2502/03 (2013.01); C12N 2509/00 (2013.01)]

4 Claims

1. A method for the treatment or prevention one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, wherein the disorders are selected from: cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies, infectious diseases or diseases associated to tissue loss, the method comprising

the administration to a patient in need thereof a therapeutically effective amount of an isolated non-cancerous non-menstrual uterine cervix mesenchymal stem cell, a cell population comprising the isolated stem cell, or a conditioned medium obtained from the culture of said cell,

wherein the isolated non-menstrual uterine cervix mesenchymal stem cell (a) expresses the cell markers CD29, CD44, CD73, CD90, CD105, vimentin, cytokeratin (CKAE1AE3), Klf4, Oct4, and Sox-2; (b) does not express CD34, CD117, p63, and at least one cell marker selected from the group consisting of desmin, actin HHF35, β-catenin, E-cadherin, CD133, HLA-DR, TRA1-81, CD45, and CD31.